Cargando…

Cellular/intramuscular myxoma and grade I myxofibrosarcoma are characterized by distinct genetic alterations and specific composition of their extracellular matrix

Cellular myxoma and grade I myxofibrosarcoma are mesenchymal tumours that are characterized by their abundant myxoid extracellular matrix (ECM). Despite their histological overlap, they differ clinically. Diagnosis is therefore difficult though important. We investigated their (cyto) genetics and EC...

Descripción completa

Detalles Bibliográficos
Autores principales: Willems, Stefan M, Mohseny, Alex B, Balog, Crina, Sewrajsing, Raj, Briaire-de Bruijn, Inge H, Knijnenburg, Jeroen, Cleton-Jansen, Anne-Marie, Sciot, Raf, Fletcher, Christopher D M, Deelder, André M, Szuhai, Karoly, Hensbergen, Paul J, Hogendoorn, Pancras C W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4496143/
https://www.ncbi.nlm.nih.gov/pubmed/19320777
http://dx.doi.org/10.1111/j.1582-4934.2009.00747.x
_version_ 1782380355842473984
author Willems, Stefan M
Mohseny, Alex B
Balog, Crina
Sewrajsing, Raj
Briaire-de Bruijn, Inge H
Knijnenburg, Jeroen
Cleton-Jansen, Anne-Marie
Sciot, Raf
Fletcher, Christopher D M
Deelder, André M
Szuhai, Karoly
Hensbergen, Paul J
Hogendoorn, Pancras C W
author_facet Willems, Stefan M
Mohseny, Alex B
Balog, Crina
Sewrajsing, Raj
Briaire-de Bruijn, Inge H
Knijnenburg, Jeroen
Cleton-Jansen, Anne-Marie
Sciot, Raf
Fletcher, Christopher D M
Deelder, André M
Szuhai, Karoly
Hensbergen, Paul J
Hogendoorn, Pancras C W
author_sort Willems, Stefan M
collection PubMed
description Cellular myxoma and grade I myxofibrosarcoma are mesenchymal tumours that are characterized by their abundant myxoid extracellular matrix (ECM). Despite their histological overlap, they differ clinically. Diagnosis is therefore difficult though important. We investigated their (cyto) genetics and ECM. GNAS1-activating mutations have been described in intramuscular myxoma, and lead to downstream activation of cFos. KRAS and TP53 mutations are commonly involved in sarcomagenesis whereby KRAS subsequently activates c-Fos. A well-documented series of intramuscular myxoma (three typical cases and seven cases of the more challenging cellular variant) and grade I myxofibrosarcoma (n= 10) cases were karyotyped, analyzed for GNAS1, KRAS and TP53 mutations and downstream activation of c-Fos mRNA and protein expression. ECM was studied by liquid chromatography mass spectrometry and expression of proteins identified was validated by immunohistochemistry and qPCR. Grade I myxofibrosarcoma showed variable, non-specific cyto-genetic aberrations in 83,5% of cases (n= 6) whereas karyotypes of intramuscular myxoma were all normal (n= 7). GNAS1-activating mutations were exclusively found in 50% of intramuscular myxoma. Both tumour types showed over-expression of c-Fos mRNA and protein. No mutations in KRAS codon 12/13 or in TP53 were detected. Liquid chromatography mass spectrometry revealed structural proteins (collagen types I, VI, XII, XIV and decorin) in grade I myxofibrosarcoma lacking in intramuscular myxoma. This was confirmed by immunohistochemistry and qPCR. Intramuscular/cellular myxoma and grade I myxofibrosarcoma show different molecular genetic aberrations and different composition of their ECM that probably contribute to their diverse clinical behaviour. GNAS1 mutation analysis can be helpful to distinguish intramuscular myxoma from grade I myxofibrosarcoma in selected cases.
format Online
Article
Text
id pubmed-4496143
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher John Wiley & Sons, Ltd
record_format MEDLINE/PubMed
spelling pubmed-44961432015-07-13 Cellular/intramuscular myxoma and grade I myxofibrosarcoma are characterized by distinct genetic alterations and specific composition of their extracellular matrix Willems, Stefan M Mohseny, Alex B Balog, Crina Sewrajsing, Raj Briaire-de Bruijn, Inge H Knijnenburg, Jeroen Cleton-Jansen, Anne-Marie Sciot, Raf Fletcher, Christopher D M Deelder, André M Szuhai, Karoly Hensbergen, Paul J Hogendoorn, Pancras C W J Cell Mol Med Articles Cellular myxoma and grade I myxofibrosarcoma are mesenchymal tumours that are characterized by their abundant myxoid extracellular matrix (ECM). Despite their histological overlap, they differ clinically. Diagnosis is therefore difficult though important. We investigated their (cyto) genetics and ECM. GNAS1-activating mutations have been described in intramuscular myxoma, and lead to downstream activation of cFos. KRAS and TP53 mutations are commonly involved in sarcomagenesis whereby KRAS subsequently activates c-Fos. A well-documented series of intramuscular myxoma (three typical cases and seven cases of the more challenging cellular variant) and grade I myxofibrosarcoma (n= 10) cases were karyotyped, analyzed for GNAS1, KRAS and TP53 mutations and downstream activation of c-Fos mRNA and protein expression. ECM was studied by liquid chromatography mass spectrometry and expression of proteins identified was validated by immunohistochemistry and qPCR. Grade I myxofibrosarcoma showed variable, non-specific cyto-genetic aberrations in 83,5% of cases (n= 6) whereas karyotypes of intramuscular myxoma were all normal (n= 7). GNAS1-activating mutations were exclusively found in 50% of intramuscular myxoma. Both tumour types showed over-expression of c-Fos mRNA and protein. No mutations in KRAS codon 12/13 or in TP53 were detected. Liquid chromatography mass spectrometry revealed structural proteins (collagen types I, VI, XII, XIV and decorin) in grade I myxofibrosarcoma lacking in intramuscular myxoma. This was confirmed by immunohistochemistry and qPCR. Intramuscular/cellular myxoma and grade I myxofibrosarcoma show different molecular genetic aberrations and different composition of their ECM that probably contribute to their diverse clinical behaviour. GNAS1 mutation analysis can be helpful to distinguish intramuscular myxoma from grade I myxofibrosarcoma in selected cases. John Wiley & Sons, Ltd 2009-07 2009-03-13 /pmc/articles/PMC4496143/ /pubmed/19320777 http://dx.doi.org/10.1111/j.1582-4934.2009.00747.x Text en © 2009 The Authors Journal compilation © 2009 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
spellingShingle Articles
Willems, Stefan M
Mohseny, Alex B
Balog, Crina
Sewrajsing, Raj
Briaire-de Bruijn, Inge H
Knijnenburg, Jeroen
Cleton-Jansen, Anne-Marie
Sciot, Raf
Fletcher, Christopher D M
Deelder, André M
Szuhai, Karoly
Hensbergen, Paul J
Hogendoorn, Pancras C W
Cellular/intramuscular myxoma and grade I myxofibrosarcoma are characterized by distinct genetic alterations and specific composition of their extracellular matrix
title Cellular/intramuscular myxoma and grade I myxofibrosarcoma are characterized by distinct genetic alterations and specific composition of their extracellular matrix
title_full Cellular/intramuscular myxoma and grade I myxofibrosarcoma are characterized by distinct genetic alterations and specific composition of their extracellular matrix
title_fullStr Cellular/intramuscular myxoma and grade I myxofibrosarcoma are characterized by distinct genetic alterations and specific composition of their extracellular matrix
title_full_unstemmed Cellular/intramuscular myxoma and grade I myxofibrosarcoma are characterized by distinct genetic alterations and specific composition of their extracellular matrix
title_short Cellular/intramuscular myxoma and grade I myxofibrosarcoma are characterized by distinct genetic alterations and specific composition of their extracellular matrix
title_sort cellular/intramuscular myxoma and grade i myxofibrosarcoma are characterized by distinct genetic alterations and specific composition of their extracellular matrix
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4496143/
https://www.ncbi.nlm.nih.gov/pubmed/19320777
http://dx.doi.org/10.1111/j.1582-4934.2009.00747.x
work_keys_str_mv AT willemsstefanm cellularintramuscularmyxomaandgradeimyxofibrosarcomaarecharacterizedbydistinctgeneticalterationsandspecificcompositionoftheirextracellularmatrix
AT mohsenyalexb cellularintramuscularmyxomaandgradeimyxofibrosarcomaarecharacterizedbydistinctgeneticalterationsandspecificcompositionoftheirextracellularmatrix
AT balogcrina cellularintramuscularmyxomaandgradeimyxofibrosarcomaarecharacterizedbydistinctgeneticalterationsandspecificcompositionoftheirextracellularmatrix
AT sewrajsingraj cellularintramuscularmyxomaandgradeimyxofibrosarcomaarecharacterizedbydistinctgeneticalterationsandspecificcompositionoftheirextracellularmatrix
AT briairedebruijningeh cellularintramuscularmyxomaandgradeimyxofibrosarcomaarecharacterizedbydistinctgeneticalterationsandspecificcompositionoftheirextracellularmatrix
AT knijnenburgjeroen cellularintramuscularmyxomaandgradeimyxofibrosarcomaarecharacterizedbydistinctgeneticalterationsandspecificcompositionoftheirextracellularmatrix
AT cletonjansenannemarie cellularintramuscularmyxomaandgradeimyxofibrosarcomaarecharacterizedbydistinctgeneticalterationsandspecificcompositionoftheirextracellularmatrix
AT sciotraf cellularintramuscularmyxomaandgradeimyxofibrosarcomaarecharacterizedbydistinctgeneticalterationsandspecificcompositionoftheirextracellularmatrix
AT fletcherchristopherdm cellularintramuscularmyxomaandgradeimyxofibrosarcomaarecharacterizedbydistinctgeneticalterationsandspecificcompositionoftheirextracellularmatrix
AT deelderandrem cellularintramuscularmyxomaandgradeimyxofibrosarcomaarecharacterizedbydistinctgeneticalterationsandspecificcompositionoftheirextracellularmatrix
AT szuhaikaroly cellularintramuscularmyxomaandgradeimyxofibrosarcomaarecharacterizedbydistinctgeneticalterationsandspecificcompositionoftheirextracellularmatrix
AT hensbergenpaulj cellularintramuscularmyxomaandgradeimyxofibrosarcomaarecharacterizedbydistinctgeneticalterationsandspecificcompositionoftheirextracellularmatrix
AT hogendoornpancrascw cellularintramuscularmyxomaandgradeimyxofibrosarcomaarecharacterizedbydistinctgeneticalterationsandspecificcompositionoftheirextracellularmatrix